Docstoc

Venous Valve, System, And Method With Sinus Pocket - Patent 7569071

Document Sample
Venous Valve, System, And Method With Sinus Pocket - Patent 7569071 Powered By Docstoc
					


United States Patent: 7569071


































 
( 1 of 1 )



	United States Patent 
	7,569,071



 Haverkost
,   et al.

 
August 4, 2009




Venous valve, system, and method with sinus pocket



Abstract

A venous valve with a frame and valve leaflets that provide a sinus
     pocket. The venous valve provides for unidirectional flow of a liquid
     through the valve.


 
Inventors: 
 Haverkost; Patrick A. (Brooklyn Center, MN), Hill; Jason P. (Brooklyn Park, MN), Shoemaker; Susan M. (Elk River, MN) 
 Assignee:


Boston Scientific Scimed, Inc.
 (Maple Grove, 
MN)





Appl. No.:
                    
11/232,403
  
Filed:
                      
  September 21, 2005





  
Current U.S. Class:
  623/1.24
  
Current International Class: 
  A61F 2/06&nbsp(20060101)
  
Field of Search: 
  
  




 623/1.24-1.26,2.14,2.17,2.18,1.3-1.31
  

References Cited  [Referenced By]
U.S. Patent Documents
 
 
 
3671979
June 1972
Moulopoulos

4291420
September 1981
Reul

4787901
November 1988
Baykut

4872874
October 1989
Taheri

4935030
June 1990
Alonso

4994077
February 1991
Dobben

5002567
March 1991
Bona et al.

5141491
August 1992
Bowald

5163953
November 1992
Vince

5219355
June 1993
Parodi et al.

5254127
October 1993
Wholey et al.

5327774
July 1994
Nguyen et al.

5332402
July 1994
Teitelbaum

5370685
December 1994
Stevens

5411552
May 1995
Anderson et al.

5469868
November 1995
Reger

5480423
January 1996
Ravenscroft et al.

5500014
March 1996
Quijano et al.

5545214
August 1996
Stevens

5554185
September 1996
Block et al.

5643208
July 1997
Parodi

5693087
December 1997
Parodi

5713953
February 1998
Vallana et al.

5716370
February 1998
Williamson, IV et al.

5735859
April 1998
Fischell et al.

5741326
April 1998
Solovay

5741333
April 1998
Frid

5800506
September 1998
Perouse

5824061
October 1998
Quijano et al.

5879320
March 1999
Cazenave

5895419
April 1999
Tweden et al.

5910170
June 1999
Reimink et al.

6010531
January 2000
Donlon et al.

6042607
March 2000
Williamson, IV et al.

6139575
October 2000
Shu et al.

6287334
September 2001
Moll et al.

6312447
November 2001
Grimes

6355030
March 2002
Aldrich et al.

6402780
June 2002
Williamson, IV et al.

6419696
July 2002
Ortiz et al.

6425916
July 2002
Garrison et al.

6440164
August 2002
DiMatteo et al.

6451054
September 2002
Stevens

6454799
September 2002
Schreck

6461366
October 2002
Seguin

6503272
January 2003
Duerig et al.

6508833
January 2003
Pavcnik et al.

6564805
May 2003
Garrison et al.

6569196
May 2003
Vesely

6602286
August 2003
Strecker

6629534
October 2003
Deem et al.

6635085
October 2003
Caffey et al.

6666885
December 2003
Moe

6666886
December 2003
Tranquillo et al.

6669725
December 2003
Scott

6673109
January 2004
Cox

6676698
January 2004
McGuckin, Jr. et al.

6676702
January 2004
Mathis

6682558
January 2004
Tu et al.

6682559
January 2004
Myers et al.

6685739
February 2004
DiMatteo et al.

6692512
February 2004
Jang

6695866
February 2004
Kuehn et al.

6695878
February 2004
McGuckin, Jr. et al.

6709456
March 2004
Langberg et al.

6709457
March 2004
Otte et al.

6716241
April 2004
Wilder et al.

6716244
April 2004
Klaco

6719767
April 2004
Kimblad

6719784
April 2004
Henderson

6719786
April 2004
Ryan et al.

6719787
April 2004
Cox

6719788
April 2004
Cox

6719789
April 2004
Cox

6719790
April 2004
Brendzel et al.

6723038
April 2004
Schroeder et al.

6723122
April 2004
Yang et al.

6723123
April 2004
Kazatchkov et al.

6726715
April 2004
Sutherland

6726716
April 2004
Marquez

6726717
April 2004
Alfieri et al.

6730118
May 2004
Spenser et al.

6730121
May 2004
Ortiz et al.

6730122
May 2004
Pan et al.

6736845
May 2004
Marquez et al.

6736846
May 2004
Cox

6749630
June 2004
McCarthy et al.

6752813
June 2004
Goldfarb et al.

6752828
June 2004
Thornton

6755857
June 2004
Peterson et al.

6761734
July 2004
Suhr

6761735
July 2004
Eberhardt et al.

6764494
July 2004
Menz et al.

6764508
July 2004
Roehe et al.

6764509
July 2004
Chinn et al.

6764510
July 2004
Vidlund et al.

6767362
July 2004
Schreck

6769434
August 2004
Liddicoat et al.

6770083
August 2004
Seguin

6780200
August 2004
Jansen

6786924
September 2004
Ryan et al.

6786925
September 2004
Schoon et al.

6790229
September 2004
Berreklouw

6790230
September 2004
Beyersdorf et al.

6790231
September 2004
Liddicoat et al.

6793673
September 2004
Kowalsky et al.

6797000
September 2004
Simpson et al.

6797001
September 2004
Mathis et al.

6797002
September 2004
Spence et al.

6802860
October 2004
Cosgrove et al.

6805710
October 2004
Bolling et al.

6805711
October 2004
Quijano et al.

6810882
November 2004
Langberg et al.

6821297
November 2004
Snyders

6824562
November 2004
Mathis et al.

6830584
December 2004
Seguin

6830585
December 2004
Artof et al.

6837902
January 2005
Nguyen et al.

6840246
January 2005
Downing

6840957
January 2005
DiMatteo et al.

6846324
January 2005
Stobie

6846325
January 2005
Liddicoat

6858039
February 2005
McCarthy

6869444
March 2005
Gabbay

6872226
March 2005
Cali et al.

6875224
April 2005
Grimes

6875230
April 2005
Morita et al.

6875231
April 2005
Anduiza et al.

6881199
April 2005
Wilk et al.

6881224
April 2005
Kruse et al.

6883522
April 2005
Spence et al.

6890352
May 2005
Lentell

6890353
May 2005
Cohn et al.

6893459
May 2005
Macoviak

6893460
May 2005
Spenser et al.

6896700
May 2005
Lu et al.

6902576
June 2005
Drasler et al.

6908478
June 2005
Alferness et al.

6908481
June 2005
Cribier

6911043
June 2005
Myers et al.

6913608
July 2005
Liddicoat et al.

6916338
July 2005
Speziali

6918917
July 2005
Nguyen et al.

6921407
July 2005
Nguyen et al.

6921811
July 2005
Zamora et al.

6926715
August 2005
Hauck et al.

6926730
August 2005
Nguyen et al.

6929653
August 2005
Strecter

6932838
August 2005
Schwartz et al.

6936067
August 2005
Buchanan

6939359
September 2005
Tu et al.

6942694
September 2005
Liddicoat et al.

6945957
September 2005
Freyman

6945978
September 2005
Hyde

6945996
September 2005
Sedransk

6945997
September 2005
Huynh et al.

6949122
September 2005
Adams et al.

6951571
October 2005
Srivastava

6951573
October 2005
Dilling

6953332
October 2005
Kurk et al.

6955689
October 2005
Ryan et al.

6958076
October 2005
Acosta et al.

6962605
November 2005
Cosgrove et al.

6964682
November 2005
Nguyen-Thien-Nhon et al.

6964683
November 2005
Kowalsky et al.

6964684
November 2005
Ortiz et al.

6966925
November 2005
Stobie

6966926
November 2005
Mathis

6974464
December 2005
Quijano et al.

6974474
December 2005
Pavcnik et al.

6974476
December 2005
McGuckin, Jr. et al.

6976995
December 2005
Mathis et al.

6979350
December 2005
Moll et al.

6986775
January 2006
Morales et al.

6989027
January 2006
Allen et al.

6989028
January 2006
Lashinski et al.

6997950
February 2006
Chawla

6997951
February 2006
Solem et al.

7004176
February 2006
Lau

7007396
March 2006
Rudko et al.

7011669
March 2006
Kimblad

7011681
March 2006
Vesely

7011682
March 2006
Lahsinski et al.

7018406
March 2006
Seguin et al.

7018407
March 2006
Wright et al.

7018408
March 2006
Bailey et al.

7022134
April 2006
Quijano et al.

7025780
April 2006
Gabbay

7033390
April 2006
Johnson et al.

7037333
May 2006
Myers et al.

7037334
May 2006
Hlavka et al.

7041128
May 2006
McGuckin, Jr. et al.

7041132
May 2006
Quijano et al.

7044966
May 2006
Svanidze et al.

7044967
May 2006
Solem et al.

7048754
May 2006
Martin et al.

7048757
May 2006
Shaknovich

7052487
May 2006
Cohn et al.

7052507
May 2006
Wakuda et al.

7063722
June 2006
Marquez

7066954
June 2006
Ryan et al.

7070616
July 2006
Majercak et al.

7070618
July 2006
Streeter

7077862
July 2006
Vidlund et al.

7081131
July 2006
Thornton

7087064
August 2006
Hyde

7089051
August 2006
Javerud et al.

7090695
August 2006
Solem et al.

2001/0011187
August 2001
Pavcnik et al.

2002/0013571
January 2002
Goldfarb et al.

2002/0026216
February 2002
Grimes

2002/0082630
June 2002
Menz et al.

2002/0123802
September 2002
Snyders

2002/0151970
October 2002
Garrison et al.

2002/0178570
December 2002
Sogard et al.

2002/0183835
December 2002
Taylor et al.

2002/0183838
December 2002
Liddicoat et al.

2002/0198594
December 2002
Schreck

2003/0050694
March 2003
Yang et al.

2003/0130729
July 2003
Paniagua et al.

2003/0163194
August 2003
Quijano et al.

2003/0167071
September 2003
Martin et al.

2003/0171806
September 2003
Mathis et al.

2003/0199975
October 2003
Gabbay

2003/0229394
December 2003
Ogle et al.

2003/0229395
December 2003
Cox

2003/0233142
December 2003
Morales et al.

2003/0236568
December 2003
Hojeibane et al.

2003/0236569
December 2003
Mathis et al.

2004/0002719
January 2004
Oz et al.

2004/0003819
January 2004
St. Goar et al.

2004/0010305
January 2004
Alferness et al.

2004/0015230
January 2004
Moll et al.

2004/0015232
January 2004
Shu et al.

2004/0015233
January 2004
Jansen

2004/0019374
January 2004
Hojeibane et al.

2004/0019377
January 2004
Taylor et al.

2004/0019378
January 2004
Hlavka et al.

2004/0024447
February 2004
Haverich

2004/0024451
February 2004
Johnson et al.

2004/0024452
February 2004
Kruse et al.

2004/0030321
February 2004
Fangrow, Jr.

2004/0030381
February 2004
Shu

2004/0030382
February 2004
St. Goar et al.

2004/0030405
February 2004
Carpentier et al.

2004/0034380
February 2004
Woolfson et al.

2004/0034411
February 2004
Quijano et al.

2004/0039436
February 2004
Spenser et al.

2004/0039442
February 2004
St. Goar et al.

2004/0039443
February 2004
Solem et al.

2004/0044350
March 2004
Martin et al.

2004/0044365
March 2004
Bachman

2004/0044403
March 2004
Bischoff et al.

2004/0049207
March 2004
Goldfarb et al.

2004/0049211
March 2004
Tremulis et al.

2004/0049266
March 2004
Anduiza et al.

2004/0059351
March 2004
Eigler et al.

2004/0059411
March 2004
Strecker

2004/0059412
March 2004
Lytle, IV et al.

2004/0060161
April 2004
Leal et al.

2004/0073301
April 2004
Donlon et al.

2004/0073302
April 2004
Rourke et al.

2004/0078072
April 2004
Tu et al.

2004/0078074
April 2004
Anderson et al.

2004/0082910
April 2004
Constantz et al.

2004/0082923
April 2004
Field

2004/0082991
April 2004
Nguyen et al.

2004/0087975
May 2004
Lucatero et al.

2004/0088045
May 2004
Cox

2004/0088046
May 2004
Speziali

2004/0092858
May 2004
Wilson et al.

2004/0093060
May 2004
Seguin et al.

2004/0093070
May 2004
Hojeibane et al.

2004/0093080
May 2004
Helmus et al.

2004/0097979
May 2004
Svanidze et al.

2004/0098098
May 2004
McGuckin, Jr. et al.

2004/0098112
May 2004
DiMatteo et al.

2004/0102839
May 2004
Cohn et al.

2004/0102840
May 2004
Solem et al.

2004/0102842
May 2004
Jansen

2004/0106976
June 2004
Bailey et al.

2004/0106990
June 2004
Spence et al.

2004/0106991
June 2004
Hopkins et al.

2004/0111096
June 2004
Tu et al.

2004/0117009
June 2004
Cali et al.

2004/0122448
June 2004
Levine

2004/0122512
June 2004
Navia et al.

2004/0122513
June 2004
Navia et al.

2004/0122514
June 2004
Fogarty et al.

2004/0122515
June 2004
Chu

2004/0122516
June 2004
Fogarty et al.

2004/0127979
July 2004
Wilson et al.

2004/0127980
July 2004
Kowalsky et al.

2004/0127981
July 2004
Rahdert et al.

2004/0127982
July 2004
Machold et al.

2004/0133220
July 2004
Lashinski et al.

2004/0133267
July 2004
Lane

2004/0133273
July 2004
Cox

2004/0138742
July 2004
Myers et al.

2004/0138743
July 2004
Myers et al.

2004/0138744
July 2004
Lashinski et al.

2004/0138745
July 2004
Macoviak et al.

2004/0148018
July 2004
Carpentier et al.

2004/0148019
July 2004
Vidlund et al.

2004/0148020
July 2004
Vidlund et al.

2004/0153052
August 2004
Mathis

2004/0153146
August 2004
Lashinski et al.

2004/0153147
August 2004
Mathis

2004/0158321
August 2004
Reuter et al.

2004/0162610
August 2004
Liska et al.

2004/0167539
August 2004
Keuhn et al.

2004/0167619
August 2004
Case et al.

2004/0167620
August 2004
Ortiz et al.

2004/0172046
September 2004
Hlavka et al.

2004/0176839
September 2004
Huynh et al.

2004/0176840
September 2004
Langberg et al.

2004/0181238
September 2004
Zarbatany et al.

2004/0186444
September 2004
Daly et al.

2004/0186558
September 2004
Pavcnik et al.

2004/0186561
September 2004
McGuckin, Jr. et al.

2004/0186563
September 2004
Lobbi

2004/0186565
September 2004
Schreck

2004/0186566
September 2004
Hindrichs et al.

2004/0193191
September 2004
Starksen et al.

2004/0193253
September 2004
Thorpe et al.

2004/0193260
September 2004
Alferness et al.

2004/0199155
October 2004
Mollenauer

2004/0199183
October 2004
Oz et al.

2004/0199191
October 2004
Schwartz

2004/0204758
October 2004
Eberhardt et al.

2004/0206363
October 2004
McCarthy et al.

2004/0210240
October 2004
Saint

2004/0210301
October 2004
Obermiller

2004/0210303
October 2004
Sedransk

2004/0210304
October 2004
Seguin et al.

2004/0210305
October 2004
Shu et al.

2004/0210306
October 2004
Quijano et al.

2004/0210307
October 2004
Khairkhahan

2004/0215333
October 2004
Duran et al.

2004/0215339
October 2004
Drasler et al.

2004/0220654
November 2004
Mathis et al.

2004/0220657
November 2004
Nieminen et al.

2004/0225322
November 2004
Garrison et al.

2004/0225344
November 2004
Hoffa et al.

2004/0225348
November 2004
Case et al.

2004/0225352
November 2004
Osborne et al.

2004/0225353
November 2004
McGuckin, Jr. et al.

2004/0225354
November 2004
Allen et al.

2004/0225355
November 2004
Stevens

2004/0225356
November 2004
Frater

2004/0230117
November 2004
Tosaya et al.

2004/0230297
November 2004
Thornton

2004/0236411
November 2004
Sarac et al.

2004/0236418
November 2004
Stevens

2004/0236419
November 2004
Milo

2004/0243153
December 2004
Liddicoat et al.

2004/0243219
December 2004
Fischer et al.

2004/0243227
December 2004
Starksen et al.

2004/0243228
December 2004
Kowalsky et al.

2004/0243230
December 2004
Navia et al.

2004/0254600
December 2004
Zarbatany et al.

2004/0254636
December 2004
Flagle et al.

2004/0260276
December 2004
Rudko et al.

2004/0260317
December 2004
Bloom et al.

2004/0260322
December 2004
Rudko et al.

2004/0260389
December 2004
Case et al.

2004/0260390
December 2004
Sarac et al.

2004/0260393
December 2004
Rahdert et al.

2004/0260394
December 2004
Douk et al.

2004/0267357
December 2004
Allen et al.

2005/0004583
January 2005
Oz et al.

2005/0004667
January 2005
Swinford et al.

2005/0010285
January 2005
Lambrecht et al.

2005/0010287
January 2005
Macoviak et al.

2005/0015112
January 2005
Cohn et al.

2005/0021056
January 2005
St. Goar et al.

2005/0021136
January 2005
Xie et al.

2005/0027261
February 2005
Weaver et al.

2005/0027348
February 2005
Case et al.

2005/0027351
February 2005
Reuter et al.

2005/0027353
February 2005
Alferness et al.

2005/0033398
February 2005
Seguin

2005/0033419
February 2005
Alferness et al.

2005/0033446
February 2005
Deem et al.

2005/0038506
February 2005
Webler et al.

2005/0038507
February 2005
Alferness et al.

2005/0043790
February 2005
Seguin

2005/0043792
February 2005
Solem et al.

2005/0049679
March 2005
Taylor et al.

2005/0049692
March 2005
Numamoto et al.

2005/0049696
March 2005
Siess et al.

2005/0049697
March 2005
Sievers

2005/0054977
March 2005
Laird et al.

2005/0055079
March 2005
Duran

2005/0055087
March 2005
Starksen

2005/0055088
March 2005
Liddicoat et al.

2005/0055089
March 2005
Macoviak et al.

2005/0060029
March 2005
Le et al.

2005/0060030
March 2005
Lashinski et al.

2005/0065460
March 2005
Laird

2005/0065550
March 2005
Starksen et al.

2005/0065594
March 2005
Dimatteo et al.

2005/0065597
March 2005
Lansac

2005/0070998
March 2005
Rourke et al.

2005/0075584
April 2005
Cali

2005/0075659
April 2005
Realyvasquez et al.

2005/0075662
April 2005
Pedersen et al.

2005/0075712
April 2005
Biancucci et al.

2005/0075713
April 2005
Biancucci et al.

2005/0075717
April 2005
Nguyen et al.

2005/0075718
April 2005
Nguyen et al.

2005/0075719
April 2005
Bergheim

2005/0075720
April 2005
Nguyen et al.

2005/0075723
April 2005
Schroeder et al.

2005/0075724
April 2005
Svanidze et al.

2005/0075725
April 2005
Rowe

2005/0075726
April 2005
Svanidze et al.

2005/0075728
April 2005
Nguyen et al.

2005/0075729
April 2005
Nguyen et al.

2005/0075730
April 2005
Myers et al.

2005/0075731
April 2005
Artof et al.

2005/0080483
April 2005
Solem et al.

2005/0085900
April 2005
Case et al.

2005/0085903
April 2005
Lau

2005/0085904
April 2005
Lemmon

2005/0090846
April 2005
Pedersen et al.

2005/0096735
May 2005
Hojeibane et al.

2005/0096738
May 2005
Cali et al.

2005/0096739
May 2005
Cao

2005/0096740
May 2005
Langberg et al.

2005/0101975
May 2005
Nguyen et al.

2005/0102026
May 2005
Turner et al.

2005/0107810
May 2005
Morales et al.

2005/0107811
May 2005
Starksen et al.

2005/0107812
May 2005
Starksen et al.

2005/0107872
May 2005
Mensah et al.

2005/0113910
May 2005
Paniagua et al.

2005/0119673
June 2005
Gordon et al.

2005/0119734
June 2005
Spence et al.

2005/0119735
June 2005
Spence et al.

2005/0125011
June 2005
Spence et al.

2005/0131438
June 2005
Cohn

2005/0137449
June 2005
Nieminen et al.

2005/0137450
June 2005
Aronson et al.

2005/0137451
June 2005
Gordon et al.

2005/0137676
June 2005
Richardson et al.

2005/0137681
June 2005
Shoemaker et al.

2005/0137682
June 2005
Justino

2005/0137685
June 2005
Nieminen et al.

2005/0137686
June 2005
Salahieh et al.

2005/0137688
June 2005
Salahieh et al.

2005/0137689
June 2005
Salahieh et al.

2005/0137690
June 2005
Salahieh et al.

2005/0137691
June 2005
Salahieh et al.

2005/0137692
June 2005
Haug et al.

2005/0137693
June 2005
Haug et al.

2005/0137694
June 2005
Haug et al.

2005/0137696
June 2005
Salahieh et al.

2005/0137697
June 2005
Salahieh et al.

2005/0137698
June 2005
Salahieh et al.

2005/0137699
June 2005
Salahieh et al.

2005/0137700
June 2005
Spence et al.

2005/0137701
June 2005
Salahieh et al.

2005/0137702
June 2005
Haug et al.

2005/0143807
June 2005
Pavcnik et al.

2005/0143809
June 2005
Salahieh et al.

2005/0143810
June 2005
Dauner et al.

2005/0143811
June 2005
Realyvasquez

2005/0149014
July 2005
Hauck et al.

2005/0149179
July 2005
Mathis et al.

2005/0149180
July 2005
Mathis et al.

2005/0149181
July 2005
Eberhardt

2005/0159810
July 2005
Filsoufi

2005/0159811
July 2005
Lane

2005/0165477
July 2005
Anduiza et al.

2005/0165478
July 2005
Song

2005/0171472
August 2005
Lutter

2005/0171601
August 2005
Cosgrove et al.

2005/0177227
August 2005
Heim et al.

2005/0177228
August 2005
Solem et al.

2005/0182483
August 2005
Osborne et al.

2005/0184122
August 2005
Hlavka et al.

2005/0187614
August 2005
Agnew

2005/0187616
August 2005
Realyvasquez

2005/0187617
August 2005
Navia

2005/0192606
September 2005
Paul, Jr. et al.

2005/0192665
September 2005
Spenser et al.

2005/0197692
September 2005
Pai et al.

2005/0197693
September 2005
Pai et al.

2005/0197694
September 2005
Pai et al.

2005/0203549
September 2005
Realyvasquez

2005/0203605
September 2005
Dolan

2005/0203614
September 2005
Forster et al.

2005/0203615
September 2005
Forster et al.

2005/0203616
September 2005
Cribier

2005/0203617
September 2005
Forster et al.

2005/0203618
September 2005
Sharkawy et al.

2005/0216039
September 2005
Lederman

2005/0216077
September 2005
Mathis et al.

2005/0216078
September 2005
Starksen et al.

2005/0222675
October 2005
Sauter

2005/0222678
October 2005
Lashinski et al.

2005/0228422
October 2005
Machold et al.

2005/0228479
October 2005
Pavcnik et al.

2005/0228486
October 2005
Case et al.

2005/0228494
October 2005
Marquez

2005/0228495
October 2005
Macoviak

2005/0228496
October 2005
Mensah et al.

2005/0234541
October 2005
Hunt et al.

2005/0234546
October 2005
Nugent et al.

2005/0240200
October 2005
Bergheim

2005/0240202
October 2005
Shennib et al.

2005/0240255
October 2005
Schaeffer

2005/0240259
October 2005
Sisken et al.

2005/0240262
October 2005
White

2005/0244460
November 2005
Alferiev et al.

2005/0246013
November 2005
Gabbay

2005/0251251
November 2005
Cribier

2005/0256566
November 2005
Gabbay

2005/0261704
November 2005
Mathis

2005/0261759
November 2005
Lambrecht et al.

2005/0267493
December 2005
Schreck et al.

2005/0267560
December 2005
Bates

2005/0267565
December 2005
Dave et al.

2005/0267571
December 2005
Spence et al.

2005/0267573
December 2005
Macoviak et al.

2005/0267574
December 2005
Cohn et al.

2005/0272969
December 2005
Alferness et al.

2005/0273160
December 2005
Lashinski et al.

2005/0278015
December 2005
Dave et al.

2005/0283178
December 2005
Flagle et al.

2005/0288779
December 2005
Shaoulian et al.

2006/0000715
January 2006
Whitcher et al.

2006/0004439
January 2006
Spenser et al.

2006/0004442
January 2006
Spenser et al.

2006/0009804
January 2006
Pederson

2006/0009841
January 2006
McGuckin, Jr. et al.

2006/0009842
January 2006
Huynh et al.

2006/0013805
January 2006
Hebbel et al.

2006/0013855
January 2006
Carpenter et al.

2006/0015136
January 2006
Besselink

2006/0015178
January 2006
Moaddeb et al.

2006/0015179
January 2006
Bulman-Fleming et al.

2006/0020275
January 2006
Goldfarb et al.

2006/0020327
January 2006
Lashinski et al.

2006/0020332
January 2006
Lashinski et al.

2006/0020334
January 2006
Lashinski et al.

2006/0020335
January 2006
Kowalsky et al.

2006/0020336
January 2006
Liddicoat

2006/0025750
February 2006
Startksen et al.

2006/0025784
February 2006
Startksen et al.

2006/0025787
February 2006
Morales et al.

2006/0025854
February 2006
Lashinski et al.

2006/0025855
February 2006
Lashinski et al.

2006/0025856
February 2006
Ryan et al.

2006/0025857
February 2006
Bergheim et al.

2006/0030747
February 2006
Kantrowitz et al.

2006/0030866
February 2006
Schreck

2006/0030882
February 2006
Adams et al.

2006/0030885
February 2006
Hyde

2006/0036317
February 2006
Vidlund et al.

2006/0041305
February 2006
Lauterjung

2006/0041306
February 2006
Vidlund et al.

2006/0047297
March 2006
Case

2006/0047338
March 2006
Jenson

2006/0047343
March 2006
Oviatt et al.

2006/0052804
March 2006
Mialhe

2006/0052867
March 2006
Revuelta et al.

2006/0058817
March 2006
Starksen et al.

2006/0058865
March 2006
Case et al.

2006/0058871
March 2006
Zakay et al.

2006/0058889
March 2006
Case et al.

2006/0064115
March 2006
Allen et al.

2006/0064116
March 2006
Allen et al.

2006/0064118
March 2006
Kimblad

2006/0064174
March 2006
Zadno

2006/0069400
March 2006
Burnett et al.

2006/0069429
March 2006
Spence et al.

2006/0069430
March 2006
Rahdert et al.

2006/0074483
April 2006
Schrayer

2006/0074484
April 2006
Huber

2006/0074485
April 2006
Realyvasquez

2006/0085060
April 2006
Campbell

2006/0089708
April 2006
Osse et al.

2006/0095115
May 2006
Bladillah et al.

2006/0095125
May 2006
Chinn et al.

2006/0099326
May 2006
Keogh et al.

2006/0100697
May 2006
Casanova

2006/0100699
May 2006
Vidlund et al.

2006/0106278
May 2006
Machold et al.

2006/0106279
May 2006
Machold et al.

2006/0106456
May 2006
Machold et al.

2006/0111660
May 2006
Wolf et al.

2006/0111773
May 2006
Rittgers et al.

2006/0111774
May 2006
Samkov et al.

2006/0116572
June 2006
Case

2006/0116756
June 2006
Solem et al.

2006/0122686
June 2006
Gilad et al.

2006/0122692
June 2006
Gilad et al.

2006/0122693
June 2006
Biadillah et al.

2006/0127443
June 2006
Helmus

2006/0129235
June 2006
Seguin et al.

2006/0129236
June 2006
McCarthy

2006/0135476
June 2006
Kutryk et al.

2006/0135964
June 2006
Vesely

2006/0135967
June 2006
Realyvasquez

2006/0136044
June 2006
Osborne

2006/0136045
June 2006
Flagle et al.

2006/0136052
June 2006
Vesely

2006/0136054
June 2006
Berg et al.

2006/0142846
June 2006
Pavcnik et al.

2006/0142847
June 2006
Shaknovich

2006/0142848
June 2006
Gabbay

2006/0142854
June 2006
Alferness et al.

2006/0149358
July 2006
Zilla et al.

2006/0149360
July 2006
Schwammenthal et al.

2006/0149367
July 2006
Sieracki

2006/0149368
July 2006
Spence

2006/0161133
July 2006
Laird et al.

2006/0161248
July 2006
Case et al.

2006/0161249
July 2006
Realyvasquez et al.

2006/0161250
July 2006
Shaw

2006/0167468
July 2006
Gabbay

2006/0167541
July 2006
Lattouf

2006/0167542
July 2006
Quintessenza

2006/0167543
July 2006
Bailey et al.



 Foreign Patent Documents
 
 
 
0 380 666
Aug., 1990
EP

0 466 518
Jan., 1992
EP

2 728 457
Jun., 1996
FR

WO 88/00459
Jan., 1988
WO

WO 90/15582
Dec., 1990
WO

WO 95/01669
Jan., 1995
WO

WO 96/19159
Jun., 1996
WO

WO 98/03656
Jan., 1998
WO

WO 98/46115
Oct., 1998
WO

WO 99/04724
Feb., 1999
WO

WO 00/67679
Nov., 2000
WO

WO 01/15650
Mar., 2001
WO

WO 01/17462
Mar., 2001
WO

WO 01/66043
Sep., 2001
WO

WO 03/047468
Jun., 2003
WO

WO 03/084443
Oct., 2003
WO

WO 2004/019825
Mar., 2004
WO

WO 2004/021893
Mar., 2004
WO

WO 2004/023980
Mar., 2004
WO

WO 2004/030568
Apr., 2004
WO

WO 2004/030569
Apr., 2004
WO

WO 2004/030570
Apr., 2004
WO

WO 2004/032724
Apr., 2004
WO

WO 2004/032796
Apr., 2004
WO

WO 2004/037128
May., 2004
WO

WO 2004/037317
May., 2004
WO

WO 2004/039432
May., 2004
WO

WO 2004/043265
May., 2004
WO

WO 2004/043273
May., 2004
WO

WO 2004/043293
May., 2004
WO

WO 2004/045370
Jun., 2004
WO

WO 2004/045378
Jun., 2004
WO

WO 2004/045463
Jun., 2004
WO

WO 2004/047677
Jun., 2004
WO

WO 2004/060217
Jul., 2004
WO

WO 2004/060470
Jul., 2004
WO

WO 2004/062725
Jul., 2004
WO

WO 2004/066803
Aug., 2004
WO

WO 2004/066826
Aug., 2004
WO

WO 2004/069287
Aug., 2004
WO

WO 2004/075789
Sep., 2004
WO

WO 2004/080352
Sep., 2004
WO

WO 2004/082523
Sep., 2004
WO

WO 2004/082527
Sep., 2004
WO

WO 2004/082528
Sep., 2004
WO

WO 2004/082536
Sep., 2004
WO

WO 2004/082537
Sep., 2004
WO

WO 2004/082538
Sep., 2004
WO

WO 2004/082757
Sep., 2004
WO

WO 2004/084746
Oct., 2004
WO

WO 2004/084770
Oct., 2004
WO

WO 2004/089246
Oct., 2004
WO

WO 2004/089250
Oct., 2004
WO

WO 2004/089253
Oct., 2004
WO

WO 2004/091449
Oct., 2004
WO

WO 2004/091454
Oct., 2004
WO

WO 2004/093638
Nov., 2004
WO

WO 2004/093726
Nov., 2004
WO

WO 2004/093728
Nov., 2004
WO

WO 2004/093730
Nov., 2004
WO

WO 2004/093745
Nov., 2004
WO

WO 2004/093935
Nov., 2004
WO

WO 2004/096100
Nov., 2004
WO

WO 2004/103222
Dec., 2004
WO

WO 2004/103223
Dec., 2004
WO

WO 2004/105584
Dec., 2004
WO

WO 2004/105651
Dec., 2004
WO

WO 2004/112582
Dec., 2004
WO

WO 2004/112585
Dec., 2004
WO

WO 2004/112643
Dec., 2004
WO

WO 2004/112652
Dec., 2004
WO

WO 2004/112657
Dec., 2004
WO

WO 2004/112658
Dec., 2004
WO

WO 2005/000152
Jan., 2005
WO

WO 2005/002424
Jan., 2005
WO

WO 2005/002466
Jan., 2005
WO

WO 2005/004753
Jan., 2005
WO

WO 2005/007017
Jan., 2005
WO

WO 2005/007018
Jan., 2005
WO

WO 2005/007036
Jan., 2005
WO

WO 2005/007037
Jan., 2005
WO

WO 2005/009285
Feb., 2005
WO

WO 2005/009286
Feb., 2005
WO

WO 2005/009505
Feb., 2005
WO

WO 2005/009506
Feb., 2005
WO

WO 2005/011473
Feb., 2005
WO

WO 2005/011534
Feb., 2005
WO

WO 2005/011535
Feb., 2005
WO

WO 2005/013860
Feb., 2005
WO

WO 2005/018507
Mar., 2005
WO

WO 2005/021063
Mar., 2005
WO

WO 2005/023155
Mar., 2005
WO

WO 2005/025644
Mar., 2005
WO

WO 2005/027790
Mar., 2005
WO

WO 2005/027797
Mar., 2005
WO

WO 2005/034812
Apr., 2005
WO

WO 2005/039428
May., 2005
WO

WO 2005/039452
May., 2005
WO

WO 2005/046488
May., 2005
WO

WO 2005/046528
May., 2005
WO

WO 2005/046529
May., 2005
WO

WO 2005/046530
May., 2005
WO

WO 2005/046531
May., 2005
WO

WO 2005/048883
Jun., 2005
WO

WO 2005/049103
Jun., 2005
WO

WO 2005/051226
Jun., 2005
WO

WO 2005/055811
Jun., 2005
WO

WO 2005/055883
Jun., 2005
WO

WO 2005/058206
Jun., 2005
WO

WO 2005/065585
Jul., 2005
WO

WO 2005/065593
Jul., 2005
WO

WO 2005/065594
Jul., 2005
WO

WO 2005/070342
Aug., 2005
WO

WO 2005/070343
Aug., 2005
WO

WO 2005/072654
Aug., 2005
WO

WO 2005/072655
Aug., 2005
WO

WO 2005/079706
Sep., 2005
WO

WO 2005/082288
Sep., 2005
WO

WO 2005/082289
Sep., 2005
WO

WO 2005/084595
Sep., 2005
WO

WO 2005/087139
Sep., 2005
WO

WO 2005/087140
Sep., 2005
WO

WO 2006/000763
Jan., 2006
WO

WO 2006/000776
Jan., 2006
WO

WO 2006/002492
Jan., 2006
WO

WO 2006/004679
Jan., 2006
WO

WO 2006/005015
Jan., 2006
WO

WO 2006/009690
Jan., 2006
WO

WO 2006/011127
Feb., 2006
WO

WO 2006/012011
Feb., 2006
WO

WO 2006/012013
Feb., 2006
WO

WO 2006/012038
Feb., 2006
WO

WO 2006/012068
Feb., 2006
WO

WO 2006/012322
Feb., 2006
WO

WO 2006/019498
Feb., 2006
WO

WO 2006/026371
Mar., 2006
WO

WO 2006/026377
Mar., 2006
WO

WO 2006/026912
Mar., 2006
WO

WO 2006/027499
Mar., 2006
WO

WO 2006/028821
Mar., 2006
WO

WO 2006/029062
Mar., 2006
WO

WO 2006/031436
Mar., 2006
WO

WO 2006/031469
Mar., 2006
WO

WO 2006/032051
Mar., 2006
WO

WO 2006/034245
Mar., 2006
WO

WO 2006/035415
Apr., 2006
WO

WO 2006/041505
Apr., 2006
WO

WO 2006/044679
Apr., 2006
WO

WO 2006/048664
May., 2006
WO

WO 2006/050459
May., 2006
WO

WO 2006/050460
May., 2006
WO

WO 2006/054107
May., 2006
WO

WO 2006/054930
May., 2006
WO

WO 2006/055982
May., 2006
WO

WO 2006/060546
Jun., 2006
WO

WO 2006/063108
Jun., 2006
WO

WO 2006/063181
Jun., 2006
WO

WO 2006/063199
Jun., 2006
WO

WO 2006/064490
Jun., 2006
WO

WO 2006/065212
Jun., 2006
WO

WO 2006/065930
Jun., 2006
WO

WO 2006/066148
Jun., 2006
WO

WO 2006/066150
Jun., 2006
WO

WO 2006/069094
Jun., 2006
WO

WO 2006/070372
Jul., 2006
WO

WO 2006/073628
Jul., 2006
WO

WO 2006/076890
Jul., 2006
WO



   
 Other References 

International Search Report. Jul. 7, 2008. 6 pgs. cited by other.  
  Primary Examiner: Isabella; David


  Assistant Examiner: Ganesan; Suba


  Attorney, Agent or Firm: Brooks, Cameron & Huebsch, PLLC



Claims  

What is claimed is:

 1.  A venous valve frame, comprising: a first structural member that defines an elongate base portion having a first end, a second end, and an outer surface concentrically
arranged relative a longitudinal axis, where the outer surface provides at least two points of a perimeter of a first elliptical plane orthogonal to and passing through the longitudinal axis, and where the first structural member at each of the first end
and the second end includes a first curve and a second curve opposite the first curve with the first curve and the second curve of the first end positioned radially orthogonal to the first curve and the second curve of the second end of the base portion; a second structural member that extends between the first end and the second end of the elongate base portion to define a bulbous portion, where the outer surface of the elongate base portion and the second structural member provide at least four points
of a perimeter of a plane orthogonal to the longitudinal axis, where the plane has an area that is greater than the area of the first elliptical plane;  and a valve leaflet connection location along the first structural member of the venous valve frame.


 2.  The valve frame of claim 1, where the perimeter of the plane for the bulbous portion-defines an elliptical shape.


 3.  The valve frame of claim 2, where the first structural member defines a first axis of the elliptical shape and the second structural member defines a second axis of the elliptical shape that is twenty percent (20%) to fifty percent (50%)
greater than the first axis.


 4.  The valve frame of claim 2, where the first structural member defines a first axis of the elliptical shape and the second structural member defines a second axis of the elliptical shape that is one (1) to four (4) millimeters greater than
the length of the first axis.


 5.  The valve frame of claim 1, where the perimeter of the plane for the bulbous portion defines a round shape.


 6.  The valve frame of claim 1, where the first curve and the second curve flare away from a center longitudinal axis.


 7.  A valve frame of claim 1, where the first structural member includes surfaces defining a first opening and a second opening for the valve leaflet connection location, where the first and second openings are adjacent a region of the bulbous
portion of the valve frame and positioned opposite each other along a common axis.


 8.  The venous valve frame of claim 1, where the first elliptical plane is a circular plane.


 9.  A venous valve frame, comprising: a structural member that includes an elongate base portion and a bulbous portion, the elongate base portion having an outer surface concentrically arranged relative a longitudinal axis, where the outer
surface provides points of a perimeter of a first elliptical plane orthogonal to and passing through the longitudinal axis, and having at each of a first end and a second end of the elongate base portion a first curve and a second curve opposite the
first curve, where the first curve and the second curve of the first end is positioned radially orthogonal to the first curve and the second curve of the second end of the base portion;  and the bulbous portion defined by a portion of the outer surface
of the elongate base portion and a second structural member, where the outer surface and the second structural member provide points of a perimeter of a plane orthogonal to and passing through the longitudinal axis, where the plane has an area that is
greater than the area of the first elliptical plane;  and a valve leaflet connection location along the structural member of the venous valve frame.


 10.  The venous valve frame of claim 9, where the bulbous portion provides a surface that defines a sinus pocket.


 11.  The venous valve frame of claim 10, where the sinus pocket provides a dilated channel as compared to the elongate base portion of the venous valve frame.


 12.  The venous valve frame of claim 9, where the first elliptical plane is a circular plane.  Description  

FIELD OF THE INVENTION


The present disclosure relates to vascular medical devices, systems and methods; and more particularly to venous valves including a venous valve frame, and methods for forming and using the venous valve frame.


BACKGROUND OF THE DISCLOSURE


The venous system of the legs uses valves and muscles as part of the body's pumping mechanism to return blood to the heart.  Venous valves create one way flow to prevent blood from flowing away from the heart.  When valves fail, blood can pool in
the lower legs resulting in swelling and ulcers of the leg.  The absence of functioning venous valves can lead to chronic venous insufficiency.


Techniques for both repairing and replacing the valves exist, but are tedious and require invasive surgical procedures.  Direct and indirect valvuoplasty procedures are used to repair damaged valves.  Transposition and transplantation are used to
replace an incompetent valve.  Transposition involves moving a vein with an incompetent valve to a site with a competent valve.  Transplantation replaces an incompetent valve with a harvested valve from another venous site.


Prosthetic valves can be transplanted into the venous system, but current devices are not successful enough to see widespread usage.  One reason for this is the very high percentage of prosthetic valves reported with leaflet functional failures. 
These failures have been blamed primarily on improper sizing and tilted deployment of the prosthetic valve.  In addition, a great number of leaflets of the prosthetic valves ultimately become fused to the vein wall. 

BRIEF DESCRIPTION OF THE
DRAWINGS


FIGS. 1A and 1B illustrate an embodiment of a venous valve according to the present disclosure.


FIGS. 2A and 2B illustrate an end view of embodiments of a venous valve according to the present disclosure.


FIGS. 3A-3E illustrate embodiments of valve frame configurations according to the present disclosure.


FIG. 4 illustrates an embodiment of a system that includes a valve according to the present disclosure.


FIG. 5 illustrates an embodiment of a system that includes a valve according to the present disclosure.


FIGS. 6A, 6B and 6C illustrate an embodiment of a system that includes a valve according to the present disclosure.


FIGS. 7A, 7B and 7C illustrate an embodiment of a system that includes a valve according to the present disclosure.


FIGS. 8A, 8B and 8C illustrate an embodiment of a system that includes a valve and a catheter having radiopaque markers according to the present disclosure.


DETAILED DESCRIPTION


Embodiments of the present disclosure are directed to vascular medical devices, systems and methods for valve replacement and/or augmentation.  Particularly, the present disclosure provides venous valve frames, venous valves that utilize the
venous valve frames, and methods for forming and using the venous valve frame and the venous valve.  Various embodiments of the present disclosure can be used to replace and/or augment an incompetent valve in a body lumen.


Embodiments of the venous valve include a venous valve frame and valve leaflets that can be implanted through minimally-invasive techniques into the body lumen.  In one example, embodiments of the apparatus, system, and method for valve
replacement or augmentation may help to maintain antegrade blood flow, while decreasing retrograde blood flow in a venous system of individuals having venous insufficiency, such as venous insufficiency in the legs.  Use of valve embodiments can also be
possible in other portions of the vasculature.


The figures herein follow a numbering convention in which the first digit or digits correspond to the drawing figure number and the remaining digits identify an element or component in the drawing.  Similar elements or components between
different figures may be identified by the use of similar digits.  For example, 110 may reference element "10" in FIG. 1, and a similar element may be referenced as 210 in FIG. 2.  As will be appreciated, elements shown in the various embodiments herein
can be added, exchanged, and/or eliminated so as to provide a number of additional embodiments of valve.  In addition, discussion of features and/or attributes for an element with respect to one Fig. can also apply to the element shown in one or more
additional Figs. Embodiments illustrated in the figures are not necessarily to scale.


FIGS. 1A and 1B provide illustrations of various embodiments of a venous valve 100 of the present disclosure.  The venous valve 100 can be implanted within the fluid passageway of a body lumen, such as for replacement and/or augmentation of a
valve structure within the body lumen (e.g., a venous valve).  In one embodiment, the venous valve 100 of the present disclosure may be beneficial to regulate the flow of a bodily fluid through the body lumen in a single direction.


FIGS. 1A and 1B illustrate one embodiment of the venous valve 100.  Venous valve 100 includes a venous valve frame 102 and valve leaflets 104.  In one embodiment, the valve frame 102 and the valve leaflets 104 of the venous valve 100 can
resiliently radially collapse and expand, as will be described herein.  Among other things, the valve frame 102 and the valve leaflets 104 define a lumen 106 of the venous valve 100.  The lumen 106 allows for, amongst other things, fluid (e.g., blood) to
move through the venous valve 100.


The valve frame 102 includes a first end 108 and a second end 110 opposite the first end 108.  The first end 108 and the second end 110 define a length of the valve frame 102 and of the venous valve 100.  In one embodiment, the length of venous
valve 100 can have a number of values.  As will be appreciated, the length of venous valve 100 can be determined based upon the location into which the venous valve 100 is to be implanted.  In other words, the length of the venous valve 100 can be
patient specific.  Examples of values for the length include, but are not limited to, 20 millimeters to 80 millimeters.  Other values are also possible.


The valve frame 102 can be formed in a wide variety of configurations.  For example, the valve frame 102 can include a first structural member 112 and a second structural member 114 that together form a unitary structure with an open frame
configuration.  In one embodiment, the first structural member 112 defines an elongate base portion 116 that extends between the first end 108 and the second end 110 of the valve frame 102.  As illustrated, the first structural member 112 defines
openings through the valve frame 102 to provide at least a portion of the open frame configuration.


In addition, the first structural member 112 also defines a first perimeter value for the elongate base portion 116.  In one embodiment, the first perimeter value can be essentially constant for the length of the valve frame 102.  In other words,
the outer limit of the area defined by the elongate base portion 116 remains essentially constant along the length of the valve frame 102.  For example, an outer surface 118 of the first structural member 112 can define a circular cross-sectional area
for the elongate base portion 116.  As will be appreciated, other cross-sectional shapes are also possible, including but not limited to oval or elliptical.


In an alternative embodiment, the perimeter value changes along the length of the valve frame 102.  For example, the outer surface 118 of the first structural member 112 can change from a first cross-sectional area having a first value for the
elongate base portion 116 adjacent the first end 108 and the second end 110 to a second cross-sectional area having a second value larger than the first value.  In one embodiment, the second cross-sectional area of the outer surface 118 of the first
structural member 112 can, in conjunction with the second structural member 114 provide for a circular or round cross-sectional shape.  Other cross-sectional shapes are also possible.


In an additional embodiment, the second structural member 114 helps to define a bulbous portion 120 of the valve frame 102.  As illustrated, the second structural member 114 extends radially and longitudinally from the outer surface 118 of an
area 122 defined by the first structural member 112 to form the bulbous portion 120.  In one embodiment, the second structural member 114 helps to define a second perimeter value for the bulbous portion 120, where second perimeter value can be is greater
than the first perimeter value.


As illustrated, the outer surface 118 of the first and second structural members 112, 114 can provide a perimeter of the bulbous portion 120 and the elongate base portion 116 having a predefined shape.  For example, the first structural member
112 can define a first axis 124 of an elliptical shape and the second structural member 114 can define a second axis 126 of the elliptical shape.  In one embodiment, the length of the second axis 126 can be at least twenty percent (20%) greater than the
length of the first axis 124.  In an additional embodiment, the length of the second axis 126 can be twenty percent (20%) to fifty percent (50%) greater than the length of the first axis 124.  In a further embodiment, the length of the second axis 126
can be forty percent (40%) to forty-two percent (42%) greater than the length of the first axis 124.


In an additional embodiment, the length of the second axis 126 can be one (1) to four (4) millimeters greater than the length of the first axis 124.  As will be more fully discussed herein, this allows for a gap of one-half (0.5) to two (2)
millimeters to be maintained between a free edge of the valve leaflets 104 in their open configuration and the valve frame 102.  In one embodiment, the length of the gap between each leaflet 104 and the valve frame 102 can be, but is not necessarily,
equal.


In an additional example, the perimeter of the bulbous portion 120 and the elongate base portion 116 can have a round shape.  For example, the first axis 124 of the first structure member 112 and the second axis 126 of the second structural
member 114 can be essentially of equal length along the bulbous portion 120.


FIGS. 2A and 2B illustrate embodiments of the venous valve 200 according to the present disclosure.  The embodiments illustrated in FIGS. 2A and 2B are end views of the venous valve illustrated in FIG. 1A taken along lines 2A-2A/2B-2B.  As
discussed herein, FIG. 2A illustrates the venous valve 200 where the first structural member 212 defining the first axis 224 and the second structural member 214 defining the second axis 226 provide an elliptical shape for the bulbous portion 220 of the
valve frame 202.  FIG. 2B illustrates the venous valve 200 where the first structural member 212 defining the first axis 224 and the second structural member 214 defining the second axis 226 provide a round shape for the bulbous portion 220 of the valve
frame 202.


In addition, the first structural member 112 at each of the first end 108 and the second end 110 can include a first curve 128 and a second curve 130 opposite the first curve 128.  In one embodiment, the first structural member 112 forming the
first and second curve 128, 130 can move radially as the valve 100 radially collapses and expands.  In the various embodiments described herein, the first and second curve 128, 130 can provide a spring force (e.g., elastic potential energy) to counter
radial compression of the frame valve 102 towards its uncompressed state.  As will be appreciated, the first and second curve 128, 130 can have a number of configurations, including turns defining angles and/or arcs (e.g., having a radius of curvature). 
Additional spring force can be imparted to the frame 102 from the compression of other portions of the valve frame 102 as well.


In one embodiment, the first and second curve 128, 130 at each of the ends 108, 110 can lay opposite each other on a respective plane that is parallel to the other plane.  In addition, the first and second curve 128, 130 of the first end 108 can
be positioned radially orthogonal to the first and second curve 128, 130 of the second end 110 of the base portion 116.  As will be appreciated, the first and second curve 128, 130 at each of the ends 108, 110, however, need not either lay on planes that
are parallel relative each other and/or be positioned radially orthogonal to each other.


The compressible nature of the valve 100 can accommodate changes in body lumen size (e.g., diameter of the body lumen) by flexing to expand and/or contract to change the diameter of the valve frame 102.  In one embodiment, the first and second
curve 128, 130 in the first structural member 112 can act as springs to allow the valve 100 to resiliently radially collapse and expand.  The frame 102 can also provide sufficient contact and expansion force with the surface of a body lumen wall to
encourage fixation of the valve 100 and to prevent retrograde flow within the body lumen around the edges of the frame 102 and the surface of a lumen when combined with a closed state of the valve leaflets attached thereto.  Anchoring elements (e.g.,
barbs) can also be included with valve 100.


As will be appreciated, the first and second curve 128, 130 in the first structural member 112 can also include, but are not limited to, other shapes that allow for repeatable travel between the collapsed state and the expanded state.  For
example, the elastic regions can include integrated springs having a circular or an elliptical loop configuration.  The embodiments are not, however, limited to these configurations as other shapes are also possible.


The first structural member 112 forming the first and second curve 128, 130 can also include a radial flare 132 that curves away from a center longitudinal axis 134.  As illustrated, the radial flare 132 provides for an increase in the peripheral
frame dimension at the first end 108 and/or the second end 110 of the valve frame 102.  In one embodiment, the first structural member 112 can be pre- and/or post-treated to impart the radial flare 132.  For example, the first structural member 112
forming the first and second curve 128, 130 of the valve frame 102 could be bent to impart the radial flare 132.  The frame 102 could then be heat treated so as to fix the radial flare 132 into the first structural member 112.  Other material treatments
(e.g., plastic deformation, forging, elastic deformation with heat setting) are also possible to impart the radial flare as described herein, many of which are material specific.


The first structural member 112 and/or the second structural member 114 of the valve frame 102 can have similar and/or different cross-sectional geometries and/or cross-sectional dimensions along their length.  The similarity and/or the
differences in the cross-sectional geometries and/or cross-sectional dimensions can be based on one or more desired functions to be elicited from each portion of the frame 102.  For example, the first structural member 112 and/or the second structural
member 114 can have a similar cross-sectional geometry along its length.  Examples of cross-sectional geometries include, but are not limited to, round (e.g., circular, oval, and/or elliptical), rectangular geometries having perpendicular sides, one or
more convex sides, or one or more concave sides; semi-circular; triangular; tubular; I-shaped; T-shaped; and trapezoidal.


Alternatively, the cross-sectional dimensions of one or more geometries of the first structural member 112 and/or the second structural member 114 can change from one portion of the frame 102 to another portion of the frame 102.  For example,
portions of the first structural member 112 and/or the second structural member 114 can taper (i.e., transition) from a first geometric dimension to a second geometric dimension different than the first geometric dimension.  These embodiments, however,
are not limited to the present examples as other cross-sectional geometries and dimension are also possible.  As such, the present disclosure should not be limited to the frames provided in the illustration herein.


The valve frame 102 further includes a valve leaflet connection location 136 along the first structural member 112 of the valve frame 102.  In one embodiment, the valve leaflet connection location 136 includes portions of the first structural
member 112 that can define the area 122, as well as surfaces of the first structural member 112 that define openings through the frame 102.  For example, the first structural member 112 can include surfaces that define a first opening 138 and a second
opening 140 for the valve leaflet connection location 136.  In one embodiment, the first and second openings 138, 140 are adjacent a region of the bulbous portion 120 of the valve frame 102.  The first and second openings 138, 140 are also illustrated as
being positioned opposite each other along a common axis 144.  In the present illustration, the common axis 144 is along the first axis 124 of the shape (e.g., elliptical, round) formed by the first and second structural member 112, 114.


In an additional embodiment, the valve leaflet connection location 136 further includes a predefined portion 146 along the first structural member 112 to which the valve leaflets 104 can be attached.  As illustrated, the predefined portion 146
includes a portion of the first structural member 112 that extends between the first and second openings 138, 140 in the region of the bulbous portion 120.  In one embodiment, the valve leaflets 104 can be coupled to the valve frame 102 through the first
and second openings 138, 140 and the predefined portion 146 of the first structural member 112.


In addition to allowing the valve leaflets 104 to be coupled to the valve frame 102, the valve leaflet connection location 140 can also include predetermined dimensional relationships between portions of the valve leaflet connection location 136. For example, predetermined dimensional relationships can exist between the relative positions of the first and second openings 138, 140 and the predefined portion 146 of the first structural member 112.  These dimensional relationships can help to better
position the valve leaflets 104 in relation to the bulbous portion 120 of the valve frame 102.


For example, as illustrated the predefined portion 146 of the first structural member 112 extends away from the first and second opening 138, 140 to define a distal point 148 from the first and second openings 138, 140.  In one embodiment, the
distance between the first and second openings 138, 140 and a plane that is both orthogonal to the center longitudinal axis 134 and in contact with the distal point 148 is a predetermined length having a value of eighty-five percent (85%) of distance of
the second axis 126.


In one embodiment, the valve leaflets 104 include a first valve leaflet 150 and a second valve leaflet 152.  As illustrated, the first and second valve leaflets 150, 152 are connected to the valve leaflet connection location 136.  The first and
second valve leaflet 150, 152 have surfaces that define a commissure 154 that reversibly opens and closes for unidirectional flow of a liquid through the venous valve 100.  As used herein, the commissure 154 includes portions of the valve leaflet 104
surfaces that reversibly form a connection to allow fluid to flow through the valve 100 in essentially one direction.  For example, the surfaces of the first and second valve leaflets 150, 152 can move between a closed configuration in which fluid flow
through the lumen 106 can be restricted and an open configuration in which fluid flow through the lumen 106 can be permitted.


In addition, the first and second openings 138, 140 can be radially symmetric around the longitudinal central axis 134 of the valve frame 102.  As illustrated, the first and second openings 138, 140 can be positioned approximately one hundred
eighty (180) degrees relative each other around the longitudinal central axis 134 of the frame 102.  As will be appreciated, the first and second openings 138, 140 need not necessarily display an equally spaced symmetrical relationship as described above
in order to practice the embodiments of the present disclosure.  For example, the radial relationship can have the first and second openings 138, 140 positioned at values greater than one hundred eighty (180) degrees and less than one hundred eighty
(180) degrees relative each other around the longitudinal central axis 134 of the frame 102.


In the present example, the first and second valve leaflet 150, 152 can be coupled, as described more fully herein, to at least the valve leaflet connection location 136 and the predefined portion 146 of the valve frame 102.  As illustrated, the
valve leaflets 104 include a region 156 of the valve leaflets 104 that can move relative the valve frame 102.  The region 156 of the valve leaflets 104 can be unbound (i.e., unsupported) by the frame 102 and extends between the first and second openings
138, 140.  This configuration permits the first and second valve leaflet 150, 152 to move (e.g., pivot) relative the first and second openings 138, 140 to allow the commissure 154 to reversibly open and close for unidirectional flow of the liquid through
the venous valve 100.


In an additional embodiment, the valve leaflets 104 in their open configuration have a circumference that is less than the circumference of the valve frame 102.  For example, as illustrated, the valve leaflets 104 in their open configuration
include a gap 158 between a free edge 160 of the first and second valve leaflets 150, 152 and the bulbous portion 120 of the valve frame 102.  As discussed herein, the length of the second axis 126 can be one (1) to four (4) millimeters greater than the
length of the first axis 124.  In one embodiment, this allows for the gap 158 between the free edge 160 of each valve leaflet 104 in their open position to be one-half (0.5) to two (2) millimeters from the bulbous portion 120 of the valve frame 102.  In
one embodiment, the length of the gap 158 between each leaflet 104 and the valve frame 102 can be, but is not necessarily, equal.


In one embodiment, the first and second valve leaflets 150, 152 and the bulbous portion 120 of the valve frame 102 provide surfaces that define a sinus pocket 162.  As illustrated, the sinus pocket 162 provides a dilated channel or receptacle as
compared to the elongate base portion 116 of the venous valve 100.  In one embodiment, the presence of the sinus pocket 162 better ensures that the valve leaflets 104 do not come into contact with a significant portion of the valve frame 102 and/or the
inner wall of the vessel in which the valve 100 is implanted.  For example, the sinus pocket 162 can help prevent adhesion between the valve leaflets 104 and the vessel wall due to the presence of a volume of blood there between.


The sinus pocket 162 can also allows for improved valve leaflets 104 dynamics (e.g., opening and closing of the valve leaflets 104).  For example, the sinus pocket 162 can allow for pressure differentials across the surfaces of the valve leaflets
104 that provide for more rapid closing of the valve leaflets 104 as the retrograde blood flow begins, as will be discussed herein.


In one embodiment, the free edge 160 of the first and second valve leaflets 150, 152 is adjacent the commissure 154.  In one embodiment, the free edge 160 has a surface that defines a curve 164 between the first and second openings 138, 140.  The
curve 164 also has a bottom 166 relative the first and second openings 138, 140.  The free edge 160 can have either a non-planar or a planar configuration.  As illustrated, the free edge 160 of the first and second leaflets 150, 152 define the bottom 166
of the curve 164 that is at least a predetermined distance away from the second structural member 114 so as to define the gap 158 between the first and second leaflet 150, 152 and the second structural member 114.


In one embodiment, whether the free edge 160 has a planar or non-planar configuration can depend on what material is selected for forming the valve leaflets 104.  For example, when a stiffer material (e.g., PTFE) is used for the valve leaflets
104 the free edge 160 can have more of a concave shape than a planar or straight shape.  In other words, as illustrated in FIG. 1A, the free edge 160 transitions from a first position adjacent the first and second openings 138, 140 to a second position
lower than the first position as illustrated approximately midway between the first and second openings 138, 140.  So, the free edge 160 dips down to a low point approximately midway between and relative to the first and second openings 138, 140.  In one
embodiment, this shape allows the free edge 160 to form a catenary when the valve leaflets 104 are in their closed position, as illustrated in FIG. 1A.  In an alternative embodiment, when an elastic material is used for the valve leaflets 104 the free
edge 160 has more of a straight or planar shape.  In other words, the free edge 160 maintains essentially the same relative position around the circumference of the valve leaflets 104.


In addition, the dimensions and configuration of the valve leaflets 104 can further include proportional relationships to structures of the valve frame 102.  For example, the first and second leaflets 150, 152 can each have a predetermined length
between the distal point 148 and the bottom 166 of the curve 164 that is at least fifty percent (50%) greater than a radius of the elongate base portion 116.  In one embodiment, this dimensional relationship is taken when the valve leaflets 104 are in
their closed position.


In addition to allowing the valve leaflets 104 to be coupled to the valve frame 102, the valve leaflet connection location 136 can also include predetermined dimensional relationships between portions of the valve leaflet connection location 136. For example, predetermined dimensional relationships can exist between the relative positions of the first and second openings 138, 140 and the predefined portion 146 of the first structural member 112.  These dimensional relationships can help to better
position the valve leaflets 104 in relation to the bulbous portion 120 of the valve frame 102.


In an additional embodiment, a predetermined portion of the surfaces of the valve leaflets 150, 152 that contact to define the commissure 154 can extend parallel to the center longitudinal axis 134 of the venous valve 100 when the valve 100 is in
its closed configuration (FIG. 1A).  For example, the predetermined portion of the surfaces of the valve leaflets 150, 152 can include twenty percent (20%) of the predetermined length of the valve leaflets 150, 152 between the distal point 148 and the
bottom 166 of the curve 164.  In other words, at least twenty percent (20%) of the length of the valve leaflet 150, 152 surfaces contact to form the commissure 154.


As will be appreciated, the free edge 160 when the valve leaflets 104 are in their open configuration can have a non-round shape.  For example, the free edge 160 can have an eye shape or an oval shape with the second axis extending between the
first and second openings 138, 140.  As will be appreciated, other shapes for the valve leaflets 104 in their open configuration are also possible, including a round shape.


In one embodiment, under antegrade fluid flow (i.e., positive fluid pressure) from the second end 110 towards the first end 108 of the valve 100, the valve leaflets 104 can expand toward the inner surface 170 of the bulbous portion 120 of the
frame 102 to create an opening through which fluid is permitted to move.  In one example, the valve leaflets 104 each expand to define a semi-tubular structure having an oval cross-section when fluid opens the commissure 154.


As discussed herein, in the open configuration the gap 158 exists between the free edge 160 of the first and second valve leaflets 150, 152 and the bulbous portion 120 of the valve frame 102.  In one embodiment, the size and shape of the valve
leaflets 104 provides the gap 158 thereby preventing the valve leaflets 104 from touching the vein wall.


In addition, the size and shape of the valve leaflets 104 along with the gap 158 provides for more responsive opening and closing of the commissure 154 due to hydrodynamic relationships that are formed across the valve leaflets 104.  For example,
as the leaflets 104 are not in contact with the vessel wall and/or the bulbous portion 120 of the frame 102, the leaflets 104 can be more responsive to changes in the flow direction.  The presence of the sinus pocket 162 allows slower moving fluid (e.g.,
blood) to move into the pocket and faster moving blood on the flow side of the leaflet 104 to create a pressure differential.  This pressure differential across the valve leaflets 104 provides for the Bernoulli effect for which an increase in fluid flow
velocity there occurs simultaneously a decrease in pressure.  So, as fluid flow becomes retrograde the fluid velocity through the opening of the valve leaflets 104 is larger than the fluid flow in the sinus pocket 162.  As a result, there is a lower
pressure in the opening of the valve leaflets 104 that causes the opening to close more quickly as compared to valves without the sinus pocket 162.


In an additional embodiment, the configuration of the present embodiments allows the leaflets 104 to experience a low shear as compared to angled leaflets which are subject to high shear and direct impact with flowing blood.  This can be
attributed to the alignment of the valve leaflets 104 with the elongate base portion 116, and the adjacent vein segment, above and below the sinus pocket 162.  The sinus pocket 162 also allows for recirculation of blood within the pocket 162 that cleans
out potential thrombus buildup in the bottom of the pocket 162.


Valve 100 provides an embodiment in which the surfaces defining the commissure 154 provide a bi-leaflet configuration (i.e., a bicuspid valve) for valve 100.  Although the embodiments in FIGS. 1A and 1B illustrate and describe a bi-leaflet
configuration for the valve of the present disclosure, designs employing a different number of valve leaflets (e.g., tri-leaflet valve) may be possible.  For example, additional connection points (e.g., three or more) could be used to provide additional
valve leaflets (e.g., a tri-leaflet valve).


The embodiments of the frame described herein can also be constructed of one or more of a number of materials and in a variety of configurations.  The frame embodiments can have a unitary structure with an open frame configuration.  The frame can
also be self-expanding.  Examples of self-expanding frames include those formed from temperature-sensitive memory alloy which changes shape at a designated temperature or temperature range, such as Nitinol.  Alternatively, the self-expanding frames can
include those having a spring-bias.  In addition, the valve frame 102 can have a configuration that allows the frame embodiments be radially expandable through the use of a balloon catheter.  In this embodiment, the valve frame can be provided in
separate pieces (e.g., two frame pieces) that are delivered individually to the implant site.


The embodiments of the frame 102 can also be formed from one or more contiguous frame members.  For example, the first and second structural member 112, 114 of the frame 102 can be formed from a single contiguous member.  The single contiguous
member can be bent around an elongate tubular mandrel to form the frame.  The free ends of the single contiguous member can then be welded, fused, crimped, or otherwise joined together to form the frame.  In an additional embodiment, the first and second
structural member 112, 114 of the frame 102 can be derived (e.g., laser cut, water cut) from a single tubular segment.  In an alternative embodiment, methods of joining the first and second structural member 112, 114 of the frame 102 to create the
elastic region include, but are not limited to, welding, gluing, and fusing the frame member.  The frame 102 can be heat set by a method as is typically known for the material which forms the frame 102.


The valve frame 102 can be formed from a number of materials.  For example, the frame can be formed from a biocompatible metal, metal alloy, polymeric material, or combination thereof.  As described herein, the frame can be self-expanding or
balloon expandable.  In addition, the frame can be configured so as to have the ability to move radially between the collapsed state and the expanded state.  Examples of suitable materials include, but are not limited to, medical grade stainless steel
(e.g., 316L), titanium, tantalum, platinum alloys, niobium alloys, cobalt alloys, alginate, or combinations thereof.  Additional frame embodiments may be formed from a shape-memory material, such as shape memory plastics, polymers, and thermoplastic
materials.  Shaped memory alloys having superelastic properties generally made from ratios of nickel and titanium, commonly known as Nitinol, are also possible materials.  Other materials are also possible.


The lumen 106 can include a number of sizes.  For example, the size of the lumen can be determined based upon the type of body lumen and the body lumen size in which the valve is to be placed.  In an additional example, there can also be a
minimum value for the width for the frame that ensures that the frame will have an appropriate expansion force against the inner wall of the body lumen in which the valve is being placed.


The valve 100 can further include one or more radiopaque markers (e.g., rivets, tabs, sleeves, welds).  For example, one or more portions of the frame can be formed from a radiopaque material.  Radiopaque markers can be attached to,
electroplated, dipped and/or coated onto one or more locations along the frame.  Examples of radiopaque material include, but are not limited to, gold, tantalum, and platinum.


The position of the one or more radiopaque markers can be selected so as to provide information on the position, location and orientation (e.g., axial, directional, and/or clocking position) of the valve during its implantation.  For example,
radiopaque markers can be configured radially and longitudinally (e.g., around and along portions of the first structural member 112) on predetermined portions of the valve frame 102 to allow the radial and axial position of the valve frame 102 to be
determined.  So in one embodiment a radiograph image of the valve frame 102 taken perpendicular to the valve leaflets 104 in a first clock position can produce a first predetermined radiograph image (e.g., an imaging having the appearance of an inverted
"Y") and a radiographic image taken perpendicular to the first and second openings 138, 140 in a second clock position can produce a second predetermined radiograph image (e.g., an imaging having the appearance of an upright "Y") distinguishable from the
first predetermined radiograph image.


In one embodiment, the first and second predetermined radiograph images allow the radial position of the leaflets 104 to be better identified within the vessel.  This then allows a clocking position for the valve 100 to be determined so that the
valve can be positioned in a more natural orientation relative the compressive forces the valve will experience in situ.  In other words, determining the clocking of the valve as described herein allows the valve to be radially positioned in same
orientation as native valve that it's replacing and/or augmenting.


In one embodiment, the material of the valve leaflets 104 can be sufficiently thin and pliable so as to permit radially-collapsing of the valve leaflets 104 for delivery by catheter to a location within a body lumen.  The valve leaflets 104 can
be constructed of a fluid-impermeable biocompatible material that can be either synthetic or biologic.  Possible synthetic materials include, but are not limited to, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE),
polystyrene-polyisobutylene-polystyrene (SIBS), polyurethane, segmented poly(carbonate-urethane), Dacron, polyethlylene (PE), polyethylene terephthalate (PET), silk, Rayon, Silicone, or the like.  Possible biologic materials include, but are not limited
to, autologous, allogeneic or xenograft material.  These include explanted veins and decellularized basement membrane materials (such as non-crosslinked bladder membrane or amnionic membrane), such as small intestine submucosa (SIS) or umbilical vein. 
As will be appreciated, blends or mixtures of two or more of the materials provided herein are possible.  For example, SIBS can be blended with one or more basement membrane materials.


As described herein, a number of methods exist for attaching the valve leaflets 104 to the valve frame 102.  For example, when positioned over the inter surface 114 of the frame 102, the valve leaflets 104 can be secured to the frame members 118
through the use of biocompatible staples, glues, sutures or combinations thereof In an additional embodiment, the valve leaflets 104 can be coupled to the frame members 118 through the use of heat sealing, solvent bonding, adhesive bonding, or welding
the valve leaflets 104 to either a portion of the valve leaflets 104 (i.e., itself) and/or the frame 102.


With respect to coupling the valve leaflets 104 to the first and second openings 138, 140 and the other portions of the valve leaflet connection location 136, the valve leaflets 104 can be passed from the inner surface 170 of the first structural
member 112 and wrapped around at least a portion of the outer surface 118 adjacent the first and second openings 138, 140.  For example, securing the valve leaflets 104 at the first and second openings 138, 140 can be accomplished by making longitudinal
cuts of a predetermined length into the valve leaflets 104 adjacent the first and second openings 138, 140.  In one embodiment, each cut creates two flaps adjacent each of the first and second openings 138, 140.  The flaps can then pass through the frame
adjacent the first and second openings 138, 140 and each of the two resulting flaps can be wrapped from the inner surface 170 around the frame 102 to the outer surface 118.  The valve leaflets 104 can then be coupled to itself and/or the frame 102, as
described herein.  In addition, sutures can be passed through the first and second openings 138, 140 and the valve leaflets 104 so as to secure the valve leaflets 104 to the frame 102.  In one embodiment, providing the flaps as described allows for the
valve leaflets 104 to create a more fluid tight commissure 154 in the area adjacent the first and second openings 138, 140.


The valve leaflets 104 can have a variety of sizes and shapes.  For example, each of the valve leaflets 104 can have a similar size and shape.  Alternatively, each of the valve leaflets 104 need not have a similar size and shape (i.e., the valve
leaflets can have a different size and shape with respect to each other).


In an additional embodiment, the valve leaflets 104 can include one or more support structures, where the support structures can be integrated into and/or onto the valve leaflets 104.  For example, the valve leaflets 104 can include one or more
support ribs having a predetermined shape.  In one embodiment, the predetermined shape of the support ribs can include a curved bias so as to provide the valve leaflets 104 with a curved configuration.  Support ribs can be constructed of a flexible
material and have dimensions (e.g., thickness, width and length) and cross-sectional shape that allows the support ribs to be flexible when the valve leaflets 104 are urged into an open position, and stiff when the valve leaflets 104 are urged into a
closed position upon experiencing sufficient back flow pressure from the direction downstream from the valve.  In an additional embodiment, support ribs can also be attached to frame 102 so as to impart a spring bias to the valve leaflets in either the
open or the closed configuration.


As described herein, the valve leaflets 104 can be located over at least the inner surface 170 of the frame 102.  FIGS. 1A and 1B illustrate an embodiment of this configuration, where the material of the valve leaflets 104 extends over the inner
surface 170 and the outer surface 118 of the first structural member 112 in the valve leaflet connection location 136, as described herein.  Numerous techniques may be employed to laminate or bond the material of the valve leaflets 104 on the outer
surface 118 and/or the inner surface 170 of the frame 102, including heat setting, adhesive welding, application of uniform force and other bonding techniques.  The material of the valve leaflets 104 can also be joined to itself and/or the first
structural member 112 according to the methods described in U.S.  Patent Application Publication US 2002/0178570 to Sogard et al., which is hereby incorporated by reference in its entirety.


The material can also be coupled to the valve leaflet connection location 136 of the first structural member 112 so as to form the valve leaflets 104, as described herein.  In one embodiment, the material for the valve leaflets 104 can be in the
form of a sheet or a sleeve of material, as described herein, which can be connected to the frame 102.  Alternatively, the material for the valve leaflets 104 can initially be in the form of a liquid that can be used to cast and/or form the valve
leaflets 104 over the frame 102.  Other forms, including intermediate forms, of the valve leaflets 104 are also possible.


The material of the valve leaflets 104 can be coupled to the valve leaflet connection location 136 of the first structural member 112, including the first and second openings 138, 140, in a variety of ways so as to provide the various embodiments
of the valve of the present disclosure.  For example, a variety of fasteners can be used to couple the material of the valve leaflets 104 to the frame 102 so as to form the valve 100.  Suitable fasteners can include, but are not limited to, biocompatible
staples, glues, sutures or combinations thereof.  In an additional embodiment, the material of the valve leaflets 104 can be coupled to the frame 102 through the use of heat sealing, solvent bonding, adhesive bonding, or welding the material of the valve
leaflets 104 to either a portion of the valve leaflets 104 (i.e., itself) and/or the frame 102.


The valve leaflets 104 may also be treated and/or coated with any number of surface or material treatments.  For example, the valve leaflets 104 can be treated with one or more biologically active compounds and/or materials that may promote
and/or inhibit endothelization and/or smooth muscle cell growth of the valve leaflets 104.  Similarly, the valve leaflets 104 may be seeded and covered with cultured tissue cells (e.g., endothelial cells) derived from a either a donor or the host patient
which are attached to the valve leaflets 104.  The cultured tissue cells may be initially positioned to extend either partially or fully over the valve leaflets 104.


Valve leaflets 104 can also be capable of inhibiting thrombus formation.  Additionally, valve leaflets 104 may either prevent or facilitate tissue ingrowth there through, as the particular application for the valve 100 may dictate.  For example,
valve leaflets 104 on the outer surface 112 may be formed from a porous material to facilitate tissue ingrowth there through, while valve leaflets 104 on the inner surface 114 may be formed from a material or a treated material which inhibits tissue
ingrowth.


FIGS. 3A through 3E provide illustrations of different configurations of the valve frame 302 that have been cut to provide them in a planar view.  As illustrated, the valve frame 302 includes the first and second structural members 312, 314 that
form the elongate base portion 316 and the bulbous portion 320, respectively.  In one embodiment, the first and second structural members 312, 314 of the elongate base portion 316 and the bulbous portion 320 can include a series of interconnected
members.  These interconnected members, in one embodiment, can act as spring members to help retain the expanded shape of the valve frame 302.  In one embodiment, the interconnection of these members allows for the spring force of aligned springs
integrated into the frame 302 to be added in series so as to increase the spring force potential of the frame 302.


As illustrated, the first and second structural members 312, 314 can have a number of different configurations that provide the elongate base portion 316 and the bulbous portion 320.  As will be appreciated, other configurations are possible that
provide the bulbous portion 320 and/or the elongate base portion 316.  In addition, the bulbous portion 320 of the valve frame 302 can have a number of different configurations so as to provide the sinus pocket, as discussed herein.  For example, the
bulbous portion 320 can have one or more of a spherical, semi-spherical, oviod, semi-oviod, conical, semi-conical, torus, semi-torus, cylindrical, and semi-cylindrical.  In addition, each of two or more of the sinus pockets of the valve frame 302 can
have different shapes as discussed herein.  In other words, the need not have the same shape as the other sinus pocket of the valve frame 302.


In addition, the first and second structural members 312, 314 can each have two or more cross-sectional shapes and/or two or more different dimensions (e.g., a greater width and depth of the first and second structural members 312, 314 for the
portions of the elongate base portion 316 and/or the bulbous portion 320 as compared to the remainder of the elongate base and/or bulbous portion 316, 320.


As illustrated, the valve frame 302 can include the valve leaflet connection region 336 for coupling the valve leaflets.  As discussed herein, the valve leaflet connection region 336 can include the first and second opening 338, 340 and the
predetermined portion 346 of the first structural member 312.


FIG. 4 illustrates one embodiment of a system 480.  System 480 includes valve 400, as described herein, reversibly joined to catheter 482.  The catheter 482 includes an elongate body 484 having a proximal end 486 and a distal end 488, where valve
400 can be located between the proximal end 486 and distal end 488.  The catheter 482 can further include a lumen 490 longitudinally extending to the distal end 488.  In one embodiment, lumen 490 extends between proximal end 486 and distal end 488 of
catheter 482.  The catheter 482 can further include a guidewire lumen 492 that extends within the elongate body 484, where the guidewire lumen 492 can receive a guidewire for positioning the catheter 482 and the valve 400 within a body lumen (e.g., a
vein of a patient).


The system 480 can further include a deployment shaft 494 positioned within lumen 490, and a sheath 496 positioned adjacent the distal end 488.  In one embodiment, the valve 400 can be positioned at least partially within the sheath 496 and
adjacent the deployment shaft 494.  For example, the valve 400 can be fully or partially sheathed with the sheath 496.  The deployment shaft 494 can be moved within the lumen 490 to deploy valve 400.  For example, deployment shaft 494 can be used to push
valve 400 from sheath 496 in deploying valve 400.


FIG. 5 illustrates an additional embodiment of the system 580.  The catheter 582 includes elongate body 584, lumen 590, a retraction system 598 and a retractable sheath 596.  The retractable sheath 596 can be positioned over at least a portion of
the elongate body 584, where the retractable sheath 596 can move longitudinally along the elongate body 584.  The valve 500 can be positioned at least partially within the retractable sheath 596, where the retractable sheath 596 moves along the elongate
body 596 to deploy the valve 500.  For example, the valve 500 can be fully or partially sheathed with the sheath 596.


In one embodiment, retraction system 598 includes one or more wires 501 coupled to the retractable sheath 596, where the wires are positioned at least partially within and extend through lumen 590 in the elongate body 584.  Wires of the
retraction system 598 can then be used to retract the retractable sheath 596 in deploying valve 500.  In one embodiment, a portion of the elongate body 584 that defines the guidewire lumen 592 extends through the lumen 506 of the valve 500 to protect the
valve 500 from the movement of the guidewire 509.


FIGS. 6A-6C illustrate an additional embodiment of the system 680.  The system 680 includes a tubular sheath 611 having an elongate body 613 and a lumen 615.  The system 680 further includes a delivery shaft 617 positioned within the lumen 615 of
the tubular sheath 611.  In one embodiment, the tubular sheath 611 and the delivery shaft 617 can move longitudinally relative each other.


In one embodiment, the system 680 includes a flexible cover 619 between the tubular sheath 611 and the delivery shaft 617.  In one embodiment, the flexible cover 619 is connected to the tubular sheath 611 and the delivery shaft 617 at a fluid
tight seal 621 so as to prevent the transmission of friction from the elongate body 613 to device 600 while the elongate body 613 is retracted during the deployment cycle.  In one embodiment, this can be accomplished by creating intentional friction
surfaces between the elongate body 613 and flexible cover 619 as is demonstrated in FIG. 6A or two layers of the flexible cover 619 as is demonstrated in FIG. 6B.


In one embodiment, the tubular sheath 611, the delivery shaft 617 and the flexible cover 619 can each be formed from a number of different materials.  For the tubular sheath examples include, but are not limited to materials selected from one or
more of ePTFE, PTFE, PE, PET, silicone, and polyurethanes.  For the delivery shaft 617 examples include, but are not limited to, those selected from a metal, a metal alloy, and/or a polymer.  Examples include, but are not limited one or more of ePTFE,
PTFE, PE, nylons, PET, silicone, polyurethanes, and stainless steel (e.g., 316L).


In addition, the delivery shaft 617 can also include a configuration that imparts sufficient column rigidity to allow it to be pushed and/or pulled through the lumen 615.  For example, the delivery shaft 617 can be formed with reinforcing members
bound within the body of the delivery shaft 617 (e.g., an elongate braid of stainless steel co-extruded with a polymer).  For the flexible cover 619 examples include, but are not limited to, materials selected from one or more of ePTFE, PTFE, PE, PET,
nylons, and polyurethanes.  As will be appreciated, other materials and configurations for forming the tubular sheath 611, the delivery shaft 617 and the flexible cover 619 are also possible.


As illustrated in FIGS. 6A-6C, the valve 600 can be positioned over the delivery shaft 615 adjacent a distal end 623 of the delivery shaft 617.  In addition, the valve 600 can be held in the same relative location 625 as it is being deployed.  As
illustrated in FIG. 6A, the valve 600, a portion of the flexible cover 619 and the delivery shaft 617 can be positioned within the lumen 615 of the tubular sheath 611.  In one embodiment, the configuration illustrated in FIG. 6A allows the valve 600 to
be delivered in its compressed state to a predetermined location in the lumen of the body.  Once at the predetermined location, the sheath 611 can then be moved relative the delivery shaft 617.  FIG. 6B illustrates a situation where the sheath 611 has
been pulled over the valve 600 location 625 and at least partially over the delivery shaft 617.


As illustrated, the flexible cover 619 has a tubular configuration that folds back inside of itself (i.e., its lumen) as the tubular sheath 611 is drawn over the valve 600 and the delivery shaft 617.  In one embodiment, the lumen 615 of the
sheath 611 can contain a lubricating fluid (e.g., saline) to allow the flexible cover 619 to more easily pass over itself as illustrated.  As the tubular sheath 611 continues to be pulled back relative the delivery shaft 617 until the valve 600 is
released, as illustrated in FIG. 6C.  In one embodiment, the valve 600 can include a self-expanding frame that allows the valve 600 to deploy at location 625 once released.


FIGS. 7A-7C illustrate an additional embodiment of the system 780.  The system 780 includes a tubular sheath 711 having an elongate body 713 and a lumen 715.  The system 780 further includes a delivery shaft 717 positioned within the lumen 715 of
the tubular sheath 711.  In one embodiment, the tubular sheath 711 and the delivery shaft 717 can move longitudinally relative each other.  In contrast to the system illustrated in FIGS. 6A-6C, however, the system 780 does not include the flexible cover. As a result, the illustrated embodiment of system 780 allows for an increase in the size of the inner diameter of the elongate body 713 to be used by the delivery shaft and/or the valve 700 as compared to the elongate body that includes the flexible
cover.


In one embodiment, the tubular sheath 711 and the delivery shaft 717 can each be formed from materials and have configurations as discussed herein for FIGS. 6A-6C.  As illustrated in FIGS. 7A-7C, the valve 700 can be positioned over the delivery
shaft 715 adjacent a distal end 723 of the delivery shaft 717.  In addition, the valve 700 can be held in the same relative location 725 as it is being deployed.  As illustrated in FIG. 7A, the valve 700 and the delivery shaft 717 can be positioned
within the lumen 715 of the tubular sheath 711.  In one embodiment, the configuration illustrated in FIG. 7A allows the valve 700 to be delivered in its compressed state to a predetermined location in the lumen of the body.  Once at the predetermined
location, the sheath 711 can then be moved relative the delivery shaft 717.  FIG. 7B illustrates a situation where the sheath 711 has been pulled at least partially over the valve 700 at location 725 and at least partially over the delivery shaft 717. 
As the tubular sheath 711 continues to be pulled back relative the delivery shaft 717 the valve 700 is released, as illustrated in FIG. 7C.  In one embodiment, the valve 700 can include a self-expanding frame that allows the valve 700 to deploy at
location 725 once released.


The embodiments of the present disclosure further include methods for forming the valve of the present disclosure, as described herein.  For example, the valve frame can be formed in a number of different ways.  In one embodiment, the valve frame
can be formed by cutting a tube of material so as to form the first structural member into the elongate base portion and/or the second structural member into the bulbous portion of the valve frame.  Examples of techniques for cutting include laser
cutting and/or water jet cutting.  Other cutting techniques are also possible.  When the first structural member and the second structural member are formed separately, the two portions can be joined by a welding technique, such as laser welding.  Other
welding or bonding techniques are also possible.


Forming the second structural member into the bulbous portion that radially and longitudinally extends from the first structural member can be accomplished through a variety of techniques.  For example, the tube of material that is cut to form
the first and second structural members can either be formed with or have a bulbous portion bent into the tube of material.  In other words, the tube has the bulbous portion before cutting out the first and second structural members.


Alternatively, the first and second structural members can be cut from the tube.  The bulbous portion can then be bent into the second structural members of the valve frame to form the bulbous portion.  As discussed herein, forming the bulbous
portion can include shaping the first structural member and the second structural member into a predetermined shape, such as elliptical or round.  Other shapes for the bulbous portion are also possible.


The valve frame can then be positioned over a mandrel having surfaces that support the elongate base portion and the bulbous portion of the valve frame.  Once positioned, the valve frame can then be processed according to the material type used
for the frame.  For example, the valve frame can be heated on the mandrel to set the shape of the valve frame according to techniques as are known.


The method also includes providing the material in predefined shapes for the valve leaflets.  The valve leaflet material is applied and coupled to the valve leaflet connection location of the valve frame, as discussed herein, to provide at least
the first leaflet and the second leaflet of the valve having surfaces defining the reversibly sealable opening for unidirectional flow of a liquid through the valve.  In one embodiment, the opening defined by the valve leaflets can be configured, as
discussed herein, to create a Bernoulli Effect across the valve leaflets.


In one embodiment, coupling the material of the valve leaflets to the venous valve frame includes locating the free edge of the valve leaflets adjacent the bulbous portion to provide both the gap and the sinus pocket between the bulbous portion
in the venous valve frame and the valve leaflets.  As discussed herein, coupling the material of the valve leaflets to the venous valve frame can include configuring the valve leaflets such that at least the gap between the free edge of the valve
leaflets and the bulbous portion in the venous valve frame is maintained as the valve leaflets cycles between their opened and closed position.


In an additional example, the valve can be reversibly joined to the catheter, which can include a process of altering the shape of the valve from a first shape, for example an expanded state, to the compressed state, as described herein.  For
example, the valve can be reversibly joined with the catheter by positioning valve in the compressed state at least partially within the sheath of the catheter.  In one embodiment, positioning the valve at least partially within the sheath of the
catheter includes positioning the valve in the compressed state adjacent the deployment shaft of the catheter.  In an another embodiment, the sheath of the catheter functions as a retractable sheath, where the valve in the compressed state can be
reversibly joined with the catheter by positioning the valve at least partially within the reversible sheath of the catheter.  In a further embodiment, the catheter can include an inflatable balloon, where the balloon can be positioned at least partially
within the lumen of the valve, for example, in its compressed state.


The embodiments of the valve described herein may be used to replace, supplement, or augment valve structures within one or more lumens of the body.  For example, embodiments of the present disclosure may be used to replace an incompetent venous
valve and help to decrease backflow of blood in the venous system of the legs.


In one embodiment, the method of replacing, supplementing, and/or augmenting a valve structure can include positioning at least part of the catheter including the valve at a predetermined location within the lumen of a body.  For example, the
predetermined location can include a position within a body lumen of a venous system of a patient, such as a vein of a leg.


In one embodiment, positioning the catheter that includes the valve within the body lumen of a venous system includes introducing the catheter into the venous system of the patient using minimally invasive percutaneous, transluminal catheter
based delivery system, as is known in the art.  For example, a guidewire can be positioned within a body lumen of a patient that includes the predetermined location.  The catheter, including valve, as described herein, can be positioned over the
guidewire and the catheter advanced so as to position the valve at or adjacent the predetermined location.


As described herein, the position of the one or more radiopaque markers can be selected so as to provide information on the position, location and orientation (e.g., axial, directional, and/or clocking position) of the valve during its
implantation.  For example, radiopaque markers can be configured radially and longitudinally on predetermined portions of the valve frame and/or the elongate body of the catheter to indicate not only a longitudinal position, but also a radial position of
the valve leaflets and the valve frame (referred to as a clock position).  In one embodiment, the radiopaque markers are configures to provide radiographic images that indicate the relative radial position of the valve and valve leaflets on the catheter.


FIGS. 8A-8C provide an illustration of the radiopaque markers 827 associated with the elongate body 884 of the catheter 882.  As illustrated, the radiopaque markers 827 include a radial component 829 and a longitudinal component 831.  Depending
upon the radial position of the catheter 882, the radiopaque markers 827 can provide a different and distinguishable radiographic image.  For example, in a first position 833 illustrated in FIG. 8A the longitudinal component 831 of the radiopaque markers
827 are aligned so as to overlap.  As the catheter 882 is rotated, as illustrated in FIGS. 8B and 8C, the radiographic image of the radial component 829 and/or longitudinal component 831 of the radiopaque markers 827 changes.


The change in the relationship of the radial and longitudinal components 829, 831 as the catheter 882 is rotated allows for the relative position of the valve 800, valve frame and valve leaflets to be determined from the radiographic image.  For
example, the relative position of the first and second leaflet connection regions 826, 828 could be aligned with longitudinal component 831 of the radiopaque markers 827.  This would allow the clock position for the valve 800 to be determined so that the
valve can be positioned in a more natural orientation relative the compressive forces the valve will experience in situ.  In other words, the allowing for clocking of the valve 800 as described herein allows the valve to be radially positioned in same
orientation as native valve that it's replacing and/or augmenting.


As will be appreciated, other relative relationships between the radiopaque markers 827 and the position of the valve 800 on the catheter 882 are possible.  So, embodiments of the present disclosure should not be limited to the present example. 
For example, additional radiopaque markers 827 on the valve 800 could be used either alone or in combination with radiopaque markers 827 on the catheter 882 to help in positioning the valve 800 within a lumen.


The valve can be deployed from the catheter at the predetermined location in a number of ways, as described herein.  In one embodiment, valve of the present disclosure can be deployed and placed in a number of vascular locations.  For example,
valve can be deployed and placed within a major vein of a patient's leg.  In one embodiment, major veins include, but are not limited to, those of the peripheral venous system.  Examples of veins in the peripheral venous system include, but are not
limited to, the superficial veins such as the short saphenous vein and the greater saphenous vein, and the veins of the deep venous system, such as the popliteal vein and the femoral vein.


As described herein, the valve can be deployed from the catheter in a number of ways.  For example, the catheter can include the retractable sheath in which valve can be at least partially housed, as described herein.  Valve can be deployed by
retracting the retractable sheath of the catheter, where the valve self-expands to be positioned at the predetermined location.  In an additional example, the catheter can include a deployment shaft and sheath in which valve can be at least partially
housed adjacent the deployment shaft, as described herein.  Valve can be deployed by moving the deployment shaft through the catheter to deploy valve from the sheath, where the valve self-expands to be positioned at the predetermined location.  In an
additional embodiment, the valve can be deployed through the use of an inflatable balloon.


Once implanted, the valve can provide sufficient contact and expansion force against the body lumen wall to prevent retrograde flow between the valve and the body lumen wall.  For example, the valve can be selected to have a larger expansion
diameter than the diameter of the inner wall of the body lumen.  This can then allow valve to exert a force on the body lumen wall and accommodate changes in the body lumen diameter, while maintaining the proper placement of valve.  As described herein,
the valve can engage the lumen so as to reduce the volume of retrograde flow through and around valve.  It is, however, understood that some leaking or fluid flow may occur between the valve and the body lumen and/or through valve leaflets.


In addition, the use of both the bulbous portion and/or elongate base portion of the valve can provide a self centering aspect to valve within a body lumen.  In one embodiment, the self centering aspect resulting from the bulbous portion and/or
elongate base portion of the valve may allow valve to maintain a substantially coaxial alignment with the body lumen (e.g., such as a vein) as valve leaflets deflect between the open and closed configurations so as to better seal the reversible opening
when valve is closed.


While the present disclosure has been shown and described in detail above, it will be clear to the person skilled in the art that changes and modifications may be made without departing from the scope of the disclosure.  As such, that which is
set forth in the foregoing description and accompanying drawings is offered by way of illustration only and not as a limitation.  The actual scope of the disclosure is intended to be defined by the following claims, along with the full range of
equivalents to which such claims are entitled.


In addition, one of ordinary skill in the art will appreciate upon reading and understanding this disclosure that other variations for the disclosure described herein can be included within the scope of the present disclosure.  For example, the
frame 102 and/or the valve leaflets 104 can be coated with a non-thrombogenic biocompatible material, as are known or will be known.


In the foregoing Detailed Description, various features are grouped together in several embodiments for the purpose of streamlining the disclosure.  This method of disclosure is not to be interpreted as reflecting an intention that the
embodiments of the disclosure require more features than are expressly recited in each claim.  Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed embodiment.  Thus, the following claims
are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment.


* * * * *























				
DOCUMENT INFO
Description: The present disclosure relates to vascular medical devices, systems and methods; and more particularly to venous valves including a venous valve frame, and methods for forming and using the venous valve frame.BACKGROUND OF THE DISCLOSUREThe venous system of the legs uses valves and muscles as part of the body's pumping mechanism to return blood to the heart. Venous valves create one way flow to prevent blood from flowing away from the heart. When valves fail, blood can pool inthe lower legs resulting in swelling and ulcers of the leg. The absence of functioning venous valves can lead to chronic venous insufficiency.Techniques for both repairing and replacing the valves exist, but are tedious and require invasive surgical procedures. Direct and indirect valvuoplasty procedures are used to repair damaged valves. Transposition and transplantation are used toreplace an incompetent valve. Transposition involves moving a vein with an incompetent valve to a site with a competent valve. Transplantation replaces an incompetent valve with a harvested valve from another venous site.Prosthetic valves can be transplanted into the venous system, but current devices are not successful enough to see widespread usage. One reason for this is the very high percentage of prosthetic valves reported with leaflet functional failures. These failures have been blamed primarily on improper sizing and tilted deployment of the prosthetic valve. In addition, a great number of leaflets of the prosthetic valves ultimately become fused to the vein wall. BRIEF DESCRIPTION OF THEDRAWINGSFIGS. 1A and 1B illustrate an embodiment of a venous valve according to the present disclosure.FIGS. 2A and 2B illustrate an end view of embodiments of a venous valve according to the present disclosure.FIGS. 3A-3E illustrate embodiments of valve frame configurations according to the present disclosure.FIG. 4 illustrates an embodiment of a system that includes a valve according to the present disclosure.FIG.